These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 1316311)

  • 21. DNA-topoisomerase I and II: biologic features and their role in drug resistance.
    Russo D; Marie JP; Delmer A; Zhou D; Suberville AM; Baccarani M; Zittoun R
    Haematologica; 1993; 78(4):201-7. PubMed ID: 8294050
    [No Abstract]   [Full Text] [Related]  

  • 22. Structure-activity study of the actions of camptothecin derivatives on mammalian topoisomerase I: evidence for a specific receptor site and a relation to antitumor activity.
    Jaxel C; Kohn KW; Wani MC; Wall ME; Pommier Y
    Cancer Res; 1989 Mar; 49(6):1465-9. PubMed ID: 2538227
    [TBL] [Abstract][Full Text] [Related]  

  • 23. BN80927: a novel homocamptothecin that inhibits proliferation of human tumor cells in vitro and in vivo.
    Demarquay D; Huchet M; Coulomb H; Lesueur-Ginot L; Lavergne O; Camara J; Kasprzyk PG; Prévost G; Bigg DC
    Cancer Res; 2004 Jul; 64(14):4942-9. PubMed ID: 15256467
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Response of purified mitochondrial DNA topoisomerase I from bovine liver to camptothecin and m-AMSA.
    Lin JH; Castora FJ
    Arch Biochem Biophys; 1995 Dec; 324(2):293-9. PubMed ID: 8554321
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Development of a stable camptothecin-resistant subline of P388 leukemia with reduced topoisomerase I content.
    Eng WK; McCabe FL; Tan KB; Mattern MR; Hofmann GA; Woessner RD; Hertzberg RP; Johnson RK
    Mol Pharmacol; 1990 Oct; 38(4):471-80. PubMed ID: 2172765
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Distinct patterns of cell cycle disturbance elicited by compounds interfering with DNA topoisomerase I and II activity.
    Poot M; Hiller KH; Heimpel S; Hoehn H
    Exp Cell Res; 1995 May; 218(1):326-30. PubMed ID: 7537696
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mechanisms of resistance to topoisomerase I-targeting drugs.
    Rasheed ZA; Rubin EH
    Oncogene; 2003 Oct; 22(47):7296-304. PubMed ID: 14576839
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Camptothecin and minor-groove binder hybrid molecules: synthesis, inhibition of topoisomerase I, and anticancer cytotoxicity in vitro.
    Zhao R; al-Said NH; Sternbach DL; Lown JW
    J Med Chem; 1997 Jan; 40(2):216-25. PubMed ID: 9003520
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Molecular cloning of the genes suppressed in RVC lymphoma cells by topoisomerase inhibitors.
    Onishi Y; Kizaki H
    Biochem Biophys Res Commun; 1996 Nov; 228(1):7-13. PubMed ID: 8912629
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Schedule-dependent cytotoxicity of topotecan alone and in combination chemotherapy regimens.
    Cheng MF; Chatterjee S; Berger NA
    Oncol Res; 1994; 6(6):269-79. PubMed ID: 7865902
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Identification of topoisomerase I as the cytotoxic target of the protoberberine alkaloid coralyne.
    Gatto B; Sanders MM; Yu C; Wu HY; Makhey D; LaVoie EJ; Liu LF
    Cancer Res; 1996 Jun; 56(12):2795-800. PubMed ID: 8665516
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The cell cycle phases of DNA damage and repair initiated by topoisomerase II-targeting chemotherapeutic drugs.
    Potter AJ; Rabinovitch PS
    Mutat Res; 2005 May; 572(1-2):27-44. PubMed ID: 15790488
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Calothrixins, a new class of human DNA topoisomerase I poisons.
    Khan QA; Lu J; Hecht SM
    J Nat Prod; 2009 Mar; 72(3):438-42. PubMed ID: 19203291
    [TBL] [Abstract][Full Text] [Related]  

  • 34. DNA topoisomerase-targeting antitumor agents and drug resistance.
    Takano H; Kohno K; Matsuo K; Matsuda T; Kuwano M
    Anticancer Drugs; 1992 Aug; 3(4):323-30. PubMed ID: 1330080
    [TBL] [Abstract][Full Text] [Related]  

  • 35. DNA topoisomerase-targeting antitumor drugs can be studied in yeast.
    Nitiss J; Wang JC
    Proc Natl Acad Sci U S A; 1988 Oct; 85(20):7501-5. PubMed ID: 2845409
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Resistance to inhibitors of DNA topoisomerases.
    Sullivan DM; Ross WE
    Cancer Treat Res; 1991; 57():57-99. PubMed ID: 1686723
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Development of resistance to 9-nitro-camptothecin by human leukemia U-937 cells in vitro correlates with altered sensitivities to several anticancer drugs.
    Pantazis P; Mendoza J; DeJesus A; Early J; Shaw M; Giovanella BC
    Anticancer Drugs; 1994 Aug; 5(4):473-9. PubMed ID: 7949254
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Determinants of cellular sensitivity to topoisomerase-targeting antitumor drugs.
    D'Arpa P
    Adv Pharmacol; 1994; 29B():127-43. PubMed ID: 8996605
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Rapid chromatin reorganization induced by topoisomerase I-mediated DNA damage.
    Sun M; Duann P; Lin CT; Zhang H; Liu LF
    Ann N Y Acad Sci; 2000; 922():340-2. PubMed ID: 11193917
    [No Abstract]   [Full Text] [Related]  

  • 40. Topoisomerase I in multiple drug resistance.
    Pessina A
    Cytotechnology; 1993; 12(1-3):127-35. PubMed ID: 7764454
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.